机构称医药行业进入“创新驱动”的营收时代，关注恒生创新药ETF（159316）、医药ETF（512010）等配置价值

Group 1 - The pharmaceutical sector experienced a decline today, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index down by 1.3%, the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 1.4%, the CSI 300 Pharmaceutical and Health Index down by 1.5%, the CSI Innovative Drug Industry Index down by 1.6%, and the CSI Biotechnology Theme Index down by 1.8% [1] - Huachuang Securities stated that the fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the continuous demand for pharmaceuticals and the increasing number of unmet needs, along with pharmaceutical companies continuously increasing R&D investments to meet these demands [1] - China has become a significant participant in global innovative drug R&D, with overseas licensing heat continuing to rise year after year, marking the pharmaceutical industry’s entry into a revenue era driven by innovation [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug R&D, gathering the main players in A-share innovative drugs [5] - The index has seen a decline of 1.6%, with a rolling price-to-earnings ratio of 50.2 times and a valuation increase of 72.8% since its launch [6] - The biotechnology ETF tracks the CSI Biotechnology Theme Index, which focuses on leading biotechnology companies in the A-share market, consisting of no more than 50 stocks involved in gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [7] - The biotechnology index has declined by 1.8%, with a rolling price-to-earnings ratio of 54.7 times and a valuation increase of 63.4% since its launch [8] - The pharmaceutical ETF exclusively tracks the CSI 300 Pharmaceutical and Health Index, focusing on leading companies in the pharmaceutical and health industry within the CSI 300 Index, covering various segments of the future health industry [9] - The pharmaceutical index has declined by 1.5%, with a rolling price-to-earnings ratio of 30.4 times and a valuation increase of 43.1% since its launch [10]